Kevin Conlon

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

D. McNeel, R. Leidner, R. Wesolowski, 2023, Journal for ImmunoTherapy of Cancer.